Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
20 juil. 2023 15h07 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients....
Global Hematology Analyzer Markets Report 2023: 2020-2023 Data & CAGR Projections Through 2028
21 juin 2023 07h48 HE
|
Research and Markets
Dublin, June 21, 2023 (GLOBE NEWSWIRE) -- The "Hematology Analyzer Market" report has been added to ResearchAndMarkets.com's offering.The global market for hematology analyzers was valued at $3.8...
Nemysis Limited Announces Successful IHAT-Gut Trial
11 févr. 2023 03h00 HE
|
Nemysis ltd
DUBLIN, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Nemysis is pleased to announce the publication of the successful findings from the IHAT-Gut trial in iron-deficient anaemic patients (NCT02941081) in the...
FibroGen Reports Third Quarter 2022 Financial Results
07 nov. 2022 16h01 HE
|
FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
FibroGen to Participate at Stifel 2022 Healthcare Conference
01 nov. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
Precipio Launches New 1-Step Technology for all HemeScreen Assays
16 août 2022 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...
FibroGen to Report Second Quarter 2022 Financial Results
25 juil. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
Blood Temperature Indicator Market Worth $504.37 Mn, Globally, by 2028 at 12.9% CAGR - Exclusive Report by The Insight Partners
18 mai 2022 08h58 HE
|
The Insight Partners
New York, May 18, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Blood Temperature Indicator Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
26 avr. 2022 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 16h01 HE
|
FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...